Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DEGS1 | O15121 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | WNT3A | P56704 | 1/20 | 0.56 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30338494 | 0.86 | PTK2 (0.57) | DEGS1MEN1KMT2AWNT3A | |
| SCHEMBL23566420 | 0.84 | DEGS1 (0.75) | DEGS1MEN1KMT2ADGAT1NPC1 | |
| SCHEMBL224450 | 0.83 | WNT3A (0.61) | DEGS1MEN1KMT2AWNT3ADGAT1 | |
| SCHEMBL29359083 | 0.82 | WNT3A (0.60) | DEGS1MEN1KMT2AWNT3A | |
| SCHEMBL16238156 | 0.82 | NPC1 (0.61) | DEGS1MEN1KMT2AWNT3ANPC1 | |
| SCHEMBL24932090 | 0.82 | ALDH1A1 (0.56) | DEGS1DGAT1NPC1RAB9A | |
| SCHEMBL5125646 | 0.82 | KDR (0.60) | DEGS1MEN1KMT2AWNT3A | |
| SCHEMBL18979459 | 0.81 | DEGS1 (0.62) | DEGS1MEN1KMT2ADGAT1NPC1 | |
| SCHEMBL31672284 | 0.81 | DEGS1 (0.62) | DEGS1MEN1KMT2ADGAT1NPC1 | |
| SCHEMBL21286264 | 0.80 | WNT3A (0.78) | DEGS1MEN1KMT2AWNT3ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117242060-A | Isoindolinone compounds | 蒙特罗萨医疗公司 | 2023-12-15 | — | — | CN | disclosed |
| US-7368458-B2 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| WO-2006076597-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060155126-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060155126-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | DEGS1 157/4885MEN1 2914/4885KMT2A 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.